List of Excipients in Branded Drug FORTAZ

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teligent Pharma Inc	FORTAZ	ceftazidime	52565-105	SODIUM CARBONATE
Teligent Pharma Inc	FORTAZ	ceftazidime	52565-109	SODIUM CARBONATE

# Fortaz (Ceftazidime) Excipient Strategy and Commercial Opportunities

Last updated: October 7, 2026

Fortaz is the former branded injectable formulation of ceftazidime, a third-generation cephalosporin used against serious Gram-negative bacterial infections, including infections caused by Pseudomonas aeruginosa. Its core formulation is relatively simple: sterile ceftazidime pentahydrate powder with sodium carbonate as the principal formulation excipient. The commercial opportunity is therefore concentrated in manufacturing efficiency, ready-to-administer presentation, supply reliability, packaging, and differentiated hospital distribution rather than novel active-ingredient patent protection.

What is Fortaz and what excipients does it contain?

Fortaz contains ceftazidime pentahydrate equivalent to either 1 gram or 2 grams of ceftazidime for injection. Sodium carbonate is used to support pH control and formulation stability. The product is supplied as a sterile powder for reconstitution and does not depend on a complex excipient system, lipid carrier, preservative, or delivery technology (GlaxoSmithKline, 2011).

Attribute	Fortaz
Active ingredient	Ceftazidime pentahydrate
Drug class	Third-generation cephalosporin
Primary clinical use	Serious bacterial infections, including Pseudomonas infections
Common strengths	1 g and 2 g vials
Dosage form	Sterile powder for injection
Principal excipient	Sodium carbonate
Administration	Intravenous or intramuscular after reconstitution
Preservative system	None in the standard single-dose vial
Key formulation issue	Reconstitution, pH, stability, and container compatibility

The label identifies sodium carbonate at approximately 118 mg per 1-gram vial and 236 mg per 2-gram vial. The excipient contributes to the product’s sodium load, which matters in patients with sodium restrictions and should remain consistent with the approved labeling.

What is the formulation role of sodium carbonate?

Sodium carbonate provides an alkaline environment that supports ceftazidime stability in the dry product and after reconstitution. Ceftazidime is susceptible to degradation in aqueous solution, so the formulation must control pH, moisture exposure, and storage conditions.

The excipient strategy has four practical implications:

1. The powder must be protected from moisture during manufacture and storage.
2. Reconstituted solutions require defined in-use stability periods.
3. The container-closure system must limit water vapor transmission.
4. Any alternate buffer requires comparative stability, compatibility, and clinical-use justification.

A substitute buffer may create regulatory risk without delivering a clear commercial advantage. Sodium carbonate is inexpensive, familiar to regulators, and compatible with the legacy formulation. The stronger opportunity is often presentation technology rather than excipient replacement.

What reconstitution and stability characteristics create commercial opportunities?

Fortaz is reconstituted with approved diluents such as sterile water for injection, sodium chloride injection, or dextrose-containing solutions, depending on the route and concentration. The product label provides concentration-specific storage and use instructions. Reconstituted ceftazidime can be used in intravenous infusion systems, but stability depends on concentration, diluent, temperature, and storage duration (GlaxoSmithKline, 2011).

A manufacturer can create commercial differentiation through:

Opportunity	Commercial value	Main development burden
Ready-to-use IV bags	Reduces pharmacy compounding	Long-term solution stability and container compatibility
Pharmacy bulk package	Supports centralized hospital preparation	Aseptic handling and in-use stability
Dual-chamber vial or bag	Separates powder from diluent until use	Device development and combination-product review
Higher-concentration presentation	Reduces infusion volume	Osmolality, local tolerability, and stability
Premixed elastomeric device	Supports outpatient parenteral therapy	Device reliability and transport validation
Improved vial fill and reconstitution	Reduces preparation time	Manufacturing and human-factors validation
Low-sodium positioning	May address hospital formulary preferences	Requires reformulation and clinical comparability

The most defensible near-term opportunity is an aseptically manufactured premix or dual-chamber presentation with validated room-temperature handling. Hospitals may value reduced preparation steps, lower compounding workload, and fewer opportunities for medication error.

What excipient strategies are available for a new ceftazidime injectable?

Maintain the sodium carbonate formulation

This is the lowest-risk approach. A generic manufacturer can preserve the established excipient system while improving fill-finish operations, vial performance, packaging, or supply continuity. This strategy is most appropriate when the objective is rapid ANDA development and low formulation risk.

Develop a low-sodium formulation

A lower-sodium product could appeal to hospitals managing patients with renal, cardiac, or fluid-balance concerns. The opportunity is limited by the need to maintain ceftazidime stability and avoid changes in reconstitution behavior. A lower-sodium formulation would require comparative analytical data, stability data, impurity profiling, and potentially additional clinical-use support.

The commercial benefit may be modest because ceftazidime is generally administered for acute treatment, where antibiotic selection and dosing logistics have greater influence than sodium content. The opportunity becomes stronger if a manufacturer can reduce sodium without increasing cost or compromising shelf life.

Use an alternate buffer system

Potential alternatives include phosphate or other buffering systems, but the choice must be evaluated against ceftazidime degradation pathways, precipitation risk, pH drift, and compatibility with infusion solutions. Alternate-buffer development is difficult to justify unless the legacy sodium carbonate system creates a defined clinical, logistical, or manufacturing problem.

Use a ready-to-use liquid

A liquid product can eliminate reconstitution and reduce pharmacy labor. Its main barrier is chemical stability. Ceftazidime’s aqueous stability is less forgiving than that of many small-molecule injectables, particularly under prolonged room-temperature storage. A liquid product may therefore require refrigeration, shorter dating, specialized packaging, or a proprietary stabilizing system.

A liquid presentation is commercially attractive only if the manufacturer can achieve a useful shelf life with operationally acceptable storage requirements.

What FDA regulatory pathway applies to Fortaz alternatives?

Ceftazidime is a small-molecule antibiotic. A conventional generic product would generally proceed through an abbreviated new drug application, subject to FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, quality, sterility, and labeling (U.S. Food and Drug Administration, 2024a).

A reformulated product may not fit cleanly within the simplest generic pathway if it changes:

• Dosage form
• Route of administration
• Strength
• Reconstitution instructions
• Container-closure system
• Stability profile
• Labeling for storage or in-use conditions
• Excipients with potential clinical relevance

A ready-to-use bag or dual-chamber system may require combination-product analysis because the drug is integrated with a delivery device or specialized container. The regulatory burden increases when the formulation changes the method of administration or creates new handling instructions.

What is the Orange Book status of Fortaz and ceftazidime?

Fortaz is a legacy branded product. The commercial market is primarily supplied through generic ceftazidime injection products rather than active branded exclusivity. The Orange Book identifies approved drug products and, where applicable, patent and exclusivity information. Legacy ceftazidime injection products do not generally present the type of active, high-value patent barrier associated with newer protected anti-infective products (U.S. Food and Drug Administration, 2024b).

Exclusivity issue	Fortaz assessment
New chemical entity exclusivity	Expired
Branded product exclusivity	Expired
Biosimilar pathway	Not applicable
Generic pathway	ANDA pathway generally available
Formulation-patent exposure	Product-specific; requires current patent search
Method-of-use exposure	Limited commercial relevance for legacy ceftazidime
Orange Book leverage	Low compared with recently approved antibiotics

The central intellectual-property risk for a new product is unlikely to be the old Fortaz formulation itself. A company pursuing a differentiated presentation would need to assess patents covering premixed bags, dual-chamber containers, stabilizing excipient combinations, infusion devices, manufacturing processes, and specific storage conditions.

When does Fortaz lose exclusivity and what generic entry risks exist?

The core Fortaz and ceftazidime exclusivity periods have expired. Generic entry has already occurred, and the relevant commercial question is not whether generic competition can enter but whether a new entrant can obtain adequate margin in a price-sensitive hospital market.

Generic entry risks include:

• Multiple approved suppliers competing on contract price
• Group purchasing organization pressure
• Hospital preference for established suppliers
• Shortages caused by sterile manufacturing disruptions
• Low willingness to pay for minor formulation changes
• Procurement requirements for domestic or dual-source supply
• Switching costs for pharmacy workflow and inventory systems

A new entrant may achieve stronger economics through reliable supply, shortage mitigation, and differentiated packaging rather than through a premium price for the same powder vial.

Are there Paragraph IV challenges or biosimilar risks for Fortaz?

Paragraph IV litigation is generally associated with an ANDA applicant asserting that a listed patent is invalid, unenforceable, or not infringed. Because the core Fortaz product is an old small-molecule injectable with expired exclusivity, Paragraph IV activity is unlikely to be the primary market issue for standard ceftazidime injection.

Ceftazidime is not a biologic. Biosimilar competition does not apply. Competition arises from generic ceftazidime products, branded ceftazidime combinations such as ceftazidime-avibactam, and other antipseudomonal antibiotics.

How does Fortaz compare with ceftazidime-avibactam?

Ceftazidime-avibactam is a distinct product combining ceftazidime with the beta-lactamase inhibitor avibactam. It targets resistant Gram-negative infections and has a more complex clinical and commercial profile. Its formulation and patent estate are separate from Fortaz and ordinary ceftazidime injection.

Factor	Fortaz / ceftazidime	Ceftazidime-avibactam
Product type	Generic injectable antibiotic	Branded combination antibiotic
Formulation complexity	Low	Higher
Main excipient opportunity	Presentation and stability	Combination stability and proprietary formulation
Pricing environment	Generic and contract driven	Specialty hospital pricing
Resistance positioning	Established antipseudomonal activity	Activity against selected beta-lactamase-producing pathogens
Patent exposure	Generally limited for legacy product	More substantial, product-specific exposure
Commercial differentiation	Supply and workflow	Clinical positioning, stewardship, and resistance profile

A company seeking premium pricing would generally have a stronger opportunity with a clinically differentiated combination product than with standard Fortaz-equivalent ceftazidime.

What manufacturing and IP barriers affect commercial entry?

Sterile injectable manufacturing is the main practical barrier. A ceftazidime product requires validated aseptic processing, sterile filtration where applicable, controlled moisture exposure, container-closure integrity, particulate control, endotoxin control, and validated lyophilized or powder-fill operations.

The most relevant manufacturing risks are:

• Moisture-driven degradation
• Powder fill-weight variability
• Vial stopper and seal compatibility
• Reconstitution time and incomplete dissolution
• Particulate formation
• Container-closure integrity failures
• Supply constraints for sterile vials and stoppers
• Limited availability of qualified injectable manufacturing capacity

Potential patent positions may arise around a specific premixed formulation, stabilizer combination, dual-chamber configuration, or automated delivery system. A simple sodium-carbonate powder formulation is less likely to support durable exclusivity than a proprietary device-linked presentation.

What licensing deals and litigation affect Fortaz?

Fortaz’s original brand commercialization was associated with GlaxoSmithKline. The legacy product does not represent a major current licensing platform comparable with newer anti-infective assets. Commercial transactions are more likely to involve generic supply, contract manufacturing, hospital tenders, or licensing of delivery technology.

No broad commercial case for Fortaz depends on biosimilar licensing or active branded settlement agreements. Any investment decision should focus on current ANDA ownership, manufacturing site status, supply contracts, and patents covering a proposed differentiated presentation rather than historical brand rights.

What revenue exposure and competitive landscape should investors assess?

Standard ceftazidime injection is a mature generic market. Revenue exposure is tied to unit volume, hospital contracts, shortage conditions, manufacturing reliability, and portfolio scale. A new entrant should not assume that excipient changes alone will produce a premium.

The strongest commercial models are:

1. Low-cost, reliable vial supply for hospital tenders.
2. Ready-to-use products that reduce pharmacy labor.
3. Outpatient infusion products with simplified administration.
4. Dual-source or domestic supply for shortage-sensitive buyers.
5. Portfolio bundling with other injectable anti-infectives.

The weakest model is a minor excipient reformulation that does not reduce preparation time, improve stability, lower sodium exposure, or solve a documented supply problem.

Key Takeaways

• Fortaz is ceftazidime injection, supplied primarily as a sterile powder with sodium carbonate.
• The active-ingredient and original branded exclusivity periods have expired.
• Ceftazidime is a small molecule, so biosimilar competition does not apply.
• Standard generic competition is mature and price sensitive.
• The strongest commercial opportunities are ready-to-use bags, dual-chamber systems, improved reconstitution, and supply reliability.
• Sodium carbonate is a low-cost, established excipient with relatively low regulatory risk.
• Low-sodium or alternate-buffer formulations may offer differentiation but require substantial stability and comparability work.
• Sterile manufacturing, moisture control, container closure, and particulate control are major execution risks.
• Formulation or device patents may protect a new presentation, but the legacy Fortaz powder formulation is unlikely to provide meaningful exclusivity.
• Ceftazidime-avibactam has a different clinical, patent, and pricing profile and should not be treated as an extension of ordinary Fortaz economics.

FAQs

Is Fortaz still commercially available as a branded product?

The market is primarily supplied by generic ceftazidime injection products. Brand availability depends on the jurisdiction and supplier, while the Fortaz reference product is a legacy product with expired core exclusivity.

What is the main excipient in Fortaz injection?

Sodium carbonate is the principal formulation excipient identified in the Fortaz labeling. It supports formulation pH and stability.

Can ceftazidime be sold as a ready-to-use IV solution?

Potentially, but the product would require strong aqueous stability, validated container compatibility, acceptable storage conditions, and an FDA-compliant regulatory pathway. The development burden is materially higher than for a conventional powder vial.

Does Fortaz have biosimilar competition?

No. Ceftazidime is a small-molecule drug, so competition comes through generic drug applications rather than biosimilar applications.

What is the best commercial differentiation strategy for a new ceftazidime product?

A manufacturer is most likely to obtain commercial value from reliable sterile supply, premixed or dual-chamber packaging, reduced pharmacy preparation, outpatient-use convenience, or a documented sodium or stability advantage.

References

1. GlaxoSmithKline. (2011). Fortaz (ceftazidime for injection) prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (2024a). ANDA submissions: Product-specific guidance and generic drug development resources. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm